208 related articles for article (PubMed ID: 27796065)
1. Clinical and color Doppler ultrasound evaluation of polyacrylamide injection in HIV patients with severe facial lipoatrophy secondary to antiretroviral therapy.
Faundez E; Vega N; Vera E; Vega P; Sepulveda D; Wortsman X
Skin Res Technol; 2017 May; 23(2):243-248. PubMed ID: 27796065
[TBL] [Abstract][Full Text] [Related]
2. Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].
Lafaurie M; Dolivo M; Girard PM; May T; Bouchaud O; Carbonnel E; Madelaine I; Loze B; Porcher R; Molina JM;
HIV Med; 2013 Aug; 14(7):410-20. PubMed ID: 23432777
[TBL] [Abstract][Full Text] [Related]
3. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
[TBL] [Abstract][Full Text] [Related]
4. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy.
Negredo E; Puig J; Aldea D; Medina M; Estany C; Pérez-Alvarez N; Rodríguez-Fumaz C; Muñoz-Moreno JA; Higueras C; Gonzalez-Mestre V; Clotet B
AIDS Res Hum Retroviruses; 2009 Apr; 25(4):451-5. PubMed ID: 19320569
[TBL] [Abstract][Full Text] [Related]
5. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
Ramon Y; Fodor L; Ullmann Y
Dermatology; 2007; 214(2):151-4. PubMed ID: 17341865
[TBL] [Abstract][Full Text] [Related]
6. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of polyacrylamide hydrogel injection in the treatment of human immunodeficiency virus-related facial lipoatrophy: a 5-year follow-up.
De Santis G; Pignatti M; Baccarani A; Pedone A; Spaggiari A; Orlando G; Guaraldi G
Plast Reconstr Surg; 2012 Jan; 129(1):101-109. PubMed ID: 22186503
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study.
Guaraldi G; Orlando G; De Fazio D; De Lorenzi I; Rottino A; De Santis G; Pedone A; Spaggiari A; Baccarani A; Borghi V; Esposito R
Antivir Ther; 2005; 10(6):753-9. PubMed ID: 16218175
[TBL] [Abstract][Full Text] [Related]
9. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.
Rauso R; Curinga G; Santillo V; Corvo G; Tartaro G
J Craniofac Surg; 2011 Sep; 22(5):1684-8. PubMed ID: 21959413
[TBL] [Abstract][Full Text] [Related]
10. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study.
Mole B; Gillaizeau F; Carbonnel E; Pierre I; Brazille P; Grataloup C; Mercier S; Duracinsky M; Weiss L; Piketty C
AIDS Res Hum Retroviruses; 2012 Mar; 28(3):251-8. PubMed ID: 21801082
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
Burgess CM; Quiroga RM
J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
[TBL] [Abstract][Full Text] [Related]
12. 5-year study of a polyacrylamide hydrogel-based filler for rehabilitation of HIV-related facial lipoatrophy.
Rauso R
Aesthet Surg J; 2015 Nov; 35(8):1021-9. PubMed ID: 25953480
[TBL] [Abstract][Full Text] [Related]
13. Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, nonrandomized study.
Orlando G; Guaraldi G; De Fazio D; Rottino A; Grisotti A; Blini M; De Santis G; Pedone A; Spaggiari A; Baccarani A; Vandelli M; De Paola M; Comelli D; Nardini G; Beghetto B; Squillace N; Esposito R
AIDS Patient Care STDS; 2007 Nov; 21(11):833-42. PubMed ID: 18240893
[TBL] [Abstract][Full Text] [Related]
14. Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients.
Negredo E; Puig J; Ornelas A; Echeverría P; Bonjoch A; Estany C; Higueras C; Gonzalez-Mestre V; Clotet B
AIDS Res Hum Retroviruses; 2015 Aug; 31(8):817-21. PubMed ID: 25858612
[TBL] [Abstract][Full Text] [Related]
15. Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances.
Negredo E; Higueras C; Adell X; Martinez JC; Martinez E; Puig J; Fumaz CR; Muñoz-Moreno JA; Perez-Alvarez N; Videla S; Estany C; Cinquegrana D; Gonzalez-Mestre V; Clotet B
AIDS Patient Care STDS; 2006 Dec; 20(12):829-37. PubMed ID: 17192148
[TBL] [Abstract][Full Text] [Related]
16. Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study.
Skeie L; Bugge H; Negaard A; Bergersen BM
HIV Med; 2010 Mar; 11(3):170-7. PubMed ID: 19780861
[TBL] [Abstract][Full Text] [Related]
17. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
[TBL] [Abstract][Full Text] [Related]
18. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
Valantin MA; Aubron-Olivier C; Ghosn J; Laglenne E; Pauchard M; Schoen H; Bousquet R; Katz P; Costagliola D; Katlama C
AIDS; 2003 Nov; 17(17):2471-7. PubMed ID: 14600518
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA).
Jagdeo J; Ho D; Lo A; Carruthers A
J Am Acad Dermatol; 2015 Dec; 73(6):1040-54.e14. PubMed ID: 26481056
[TBL] [Abstract][Full Text] [Related]
20. [Correction of facial lipoatrophy with a biodegradable material in HIV-infected patients].
Carbonnel E; Claudy A
Ann Dermatol Venereol; 2005; 132(6-7 Pt 1):521-4. PubMed ID: 16142098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
